NASDAQ:LIMN
Liminatus Pharma, Inc.
Liminatus Pharma, Inc. reported net income of −$10.2M in fiscal 2025. Free cash flow was −$10.0M, and the diluted share count rose 35.7%.Summary generated from Liminatus Pharma, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$10.0M
FCF marginn/a
Share count change+35.7%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | n/a | n/a |
| Operating income | −3 | −3 |
| Net income | −4 | −10 |
| Free cash flow | n/a | −10 |
Recent filings
- 8-KNotice of delisting or listing-rule failure
Sep 29, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of a shareholder vote
Aug 4, 2026 - 8-KOther events
Jul 30, 2026 - 8-KNotice of delisting or listing-rule failure
Jul 24, 2026 - 4Insider transaction report
Jul 14, 2026 - DEF 14AProxy statement
Jul 13, 2026